David Roth Syros Pharmaceuticals, Inc. (SYRS) insider trading activity

David Roth is Chief Medical Officer of Syros Pharmaceuticals, Inc.. Currently has a direct ownership of 0 shares of SYRS, which is worth approximately $0. The most recent transaction as insider was on Nov 18, 2024, when has been sold 12,099 shares (Common Stock) at a price of $0.2 per share, resulting in proceeds of $2,419. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

David Roth Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 18 2024	SELL Open market or private sale	$2,419 $0.2 p/Share	12,099 Reduced 100.0%	0 Common Stock
Oct 31 2024	SELL Payment of exercise price or tax liability	$14,161 $2.09 p/Share	6,776 Reduced 35.9%	12,099 Common Stock
Oct 31 2024	BUY Exercise of conversion of derivative security	-	18,875 Added 50.0%	18,875 Common Stock
Apr 03 2024	SELL Open market or private sale	$51,732 $4.95 p/Share	10,451 Reduced 100.0%	0 Common Stock
Apr 02 2024	SELL Open market or private sale	$747 $4.98 p/Share	150 Reduced 1.41%	10,451 Common Stock
Apr 01 2024	SELL Payment of exercise price or tax liability	$24,227 $5.12 p/Share	4,732 Reduced 30.86%	10,601 Common Stock
Mar 31 2024	BUY Exercise of conversion of derivative security	-	15,333 Added 50.0%	15,333 Common Stock
Dec 12 2023	SELL Open market or private sale	$31,120 $4.95 p/Share	6,287 Reduced 100.0%	0 Common Stock
Dec 06 2023	SELL Open market or private sale	$24,833 $3.95 p/Share	6,287 Reduced 50.0%	6,287 Common Stock
Nov 01 2023	SELL Payment of exercise price or tax liability	$13,988 $2.22 p/Share	6,301 Reduced 33.38%	12,574 Common Stock
Oct 31 2023	BUY Exercise of conversion of derivative security	-	18,875 Added 50.0%	18,875 Common Stock
Jul 31 2023	SELL Open market or private sale	$29,024 $3.95 p/Share	7,348 Reduced 100.0%	0 Common Stock
Apr 03 2023	SELL Payment of exercise price or tax liability	$1,607 $2.58 p/Share	623 Reduced 7.82%	7,348 Common Stock
Mar 31 2023	BUY Exercise of conversion of derivative security	-	2,000 Added 20.06%	7,971 Common Stock
Apr 01 2022	SELL Payment of exercise price or tax liability	$30,555 $1.12 p/Share	27,281 Reduced 31.36%	59,719 Common Stock

David Roth

Chief Medical Officer

Cambridge, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SYRS shares.

Notify only if

Value

Insider Trading

Get notified when an Syros Pharmaceuticals, Inc. insider buys or sells SYRS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Syros Pharmaceuticals, Inc.

Track Activities on SYRS

Account